Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
In this study, we aimed to evaluate whether denosumab is associated with a reduced risk of acute renal allograft rejection compared with bisphosphonates in adult kidney transplant recipients with osteoporosis.
We conducted a retrospective target trial using data from the TriNetX database (January 2012–December 2023). Adult renal transplant recipients (≥18 years old) who received denosumab or bisphosphonates within the first-year post-transplant were identified. Overall, 3,794 recipients were screened, and 626 matched pairs were created using propensity score matching. The primary outcome was acute renal allograft rejection, and the secondary outcome was infection complications after the first-year post-transplant. Outcomes were assessed using Kaplan–Meier and Cox proportional hazards models.
In the propensity score-matched cohort, denosumab use was associated with a significantly lower risk of rejection (hazard ratio (HR), 0.49; 95% confidence interval [CI]: 0.33–0.72; p=0.0003). The effect was consistent across the age, sex, race, and thymoglobulin subgroups. The secondary outcome, the cumulative incidence of infectious complications, was not significantly different between the denosumab and bisphosphonate cohorts (p=0.4615, log-rank test). However, the denosumab cohort exhibited a non-significant increase in the incidence of infectious diseases (HR 1.07, 95% CI 0.89–1.30).
Renal transplant recipients treated with denosumab exhibited a significantly lower risk of acute rejection than those treated with bisphosphonates. These findings suggest that denosumab may serve as a dual-action therapy that supports bone health and reduces the immunological risk in renal transplant recipients with osteoporosis.
